[
  {
    "title": "海特生物股东严洁减持30万股 套现1213.8万 2022年前三季度公司净利1882.2万",
    "href": "http://stock.jrj.com.cn/2022/12/14201237213067.shtml",
    "datetime": "2022-12-14 20:12:18",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：董事严洁大宗交易减持30万股",
    "href": "http://stock.jrj.com.cn/2022/12/14174437212463.shtml",
    "datetime": "2022-12-14 17:44:33",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：取得换发后的《药品生产许可证》",
    "href": "http://stock.jrj.com.cn/2022/12/09155737201576.shtml",
    "datetime": "2022-12-09 15:57:22",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：定增申请获深交所受理",
    "href": "http://stock.jrj.com.cn/2022/11/27173337169347.shtml",
    "datetime": "2022-11-27 17:33:40",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：药品生产许可证变更 涉及增加生产范围",
    "href": "http://stock.jrj.com.cn/2022/11/08155237120374.shtml",
    "datetime": "2022-11-08 15:52:06",
    "code": "300683"
  },
  {
    "title": "海特生物2022年前三季度净利1882.2万同比增长1% 原料药及中间体业务增加",
    "href": "http://stock.jrj.com.cn/2022/10/24193237079058.shtml",
    "datetime": "2022-10-24 19:32:43",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：第三季度净亏损5.01万元",
    "href": "http://stock.jrj.com.cn/2022/10/24160337078026.shtml",
    "datetime": "2022-10-24 16:03:22",
    "code": "300683"
  },
  {
    "title": "海特生物：拟定增募资不超过3亿元",
    "href": "http://stock.jrj.com.cn/2022/08/31161436958179.shtml",
    "datetime": "2022-08-31 16:14:02",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)拟定增募资不超3亿元 用于高端原料药研发中试项目",
    "href": "http://stock.jrj.com.cn/2022/08/31161236958220.shtml",
    "datetime": "2022-08-31 16:12:50",
    "code": "300683"
  },
  {
    "title": "海特生物：2022年上半年净利同比增长超1倍",
    "href": "http://stock.jrj.com.cn/2022/08/02095336862002.shtml",
    "datetime": "2022-08-02 09:53:59",
    "code": "300683"
  },
  {
    "title": "海特生物2022年上半年净利1887.2万同比增长161.49% 在手订单充足",
    "href": "http://stock.jrj.com.cn/2022/08/01203236860571.shtml",
    "datetime": "2022-08-01 20:32:29",
    "code": "300683"
  },
  {
    "title": "海特生物披露2022年半年报 实现营收3.87亿元",
    "href": "http://stock.jrj.com.cn/2022/08/01173036859728.shtml",
    "datetime": "2022-08-01 17:30:35",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：荆门汉瑞变更药品生产许可证",
    "href": "http://stock.jrj.com.cn/2022/08/01162636859330.shtml",
    "datetime": "2022-08-01 16:26:57",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：上半年净利润增161.49%至1887.20万元",
    "href": "http://stock.jrj.com.cn/2022/08/01162436859337.shtml",
    "datetime": "2022-08-01 16:24:42",
    "code": "300683"
  },
  {
    "title": "海特生物2022年第一季度净利769.05万同比下滑47.07% 理财收益减少",
    "href": "http://stock.jrj.com.cn/2022/04/23183036437454.shtml",
    "datetime": "2022-04-23 18:30:32",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)2021年度净利2765.42万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2022/04/22185236430825.shtml",
    "datetime": "2022-04-22 18:52:58",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)一季度净利润769.05万元 同比下降47.07%",
    "href": "http://stock.jrj.com.cn/2022/04/22185136430827.shtml",
    "datetime": "2022-04-22 18:51:02",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：拟以简易程序定增募资不超3亿元",
    "href": "http://stock.jrj.com.cn/2022/03/08160634541312.shtml",
    "datetime": "2022-03-08 16:06:31",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：公司药品生产许可证变更",
    "href": "http://stock.jrj.com.cn/2022/02/14164634344898.shtml",
    "datetime": "2022-02-14 16:46:55",
    "code": "300683"
  },
  {
    "title": "海特生物2021年预计净利2650万-3400万同比扭亏为盈 CDMO业务增长",
    "href": "http://stock.jrj.com.cn/2022/01/25213034214163.shtml",
    "datetime": "2022-01-25 21:30:07",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：2021年度预盈2650万元-3400万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2022/01/25171234212697.shtml",
    "datetime": "2022-01-25 17:12:26",
    "code": "300683"
  },
  {
    "title": "【龙虎榜】海特生物1月24日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/24180334205364.shtml",
    "datetime": "2022-01-24 18:03:44",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：子公司荆门汉瑞取得药品生产许可证",
    "href": "http://stock.jrj.com.cn/2022/01/21190634183813.shtml",
    "datetime": "2022-01-21 19:06:47",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：董事严洁亲属短线交易公司股票",
    "href": "http://stock.jrj.com.cn/2021/12/30192134087889.shtml",
    "datetime": "2021-12-30 19:21:34",
    "code": "300683"
  },
  {
    "title": "【龙虎榜】海特生物12月20日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/12/20180334035341.shtml",
    "datetime": "2021-12-20 18:03:24",
    "code": "300683"
  },
  {
    "title": "海特生物：重组蛋白类靶向抗肿瘤新药上市许可申请获受理",
    "href": "http://stock.jrj.com.cn/2021/12/17155134031675.shtml",
    "datetime": "2021-12-17 15:51:11",
    "code": "300683"
  },
  {
    "title": "海特生物选举陈亚为董事长 第三季度公司净利1141.89万",
    "href": "http://stock.jrj.com.cn/2021/12/10211033996180.shtml",
    "datetime": "2021-12-10 21:10:57",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：拟使用不超9亿元的闲置募集资金及自有资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/11/24182333915033.shtml",
    "datetime": "2021-11-24 18:23:50",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：以2281.6万元取得北京沙东6.9416%的股权",
    "href": "http://stock.jrj.com.cn/2021/11/15210533856136.shtml",
    "datetime": "2021-11-15 21:05:51",
    "code": "300683"
  },
  {
    "title": "扭亏为盈，海特生物2021年前三季度净利润1863.61万元",
    "href": "http://stock.jrj.com.cn/2021/10/28173733770144.shtml",
    "datetime": "2021-10-28 17:37:20",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：前三季度净利升277.04%至1863.61万元",
    "href": "http://stock.jrj.com.cn/2021/10/28163233769328.shtml",
    "datetime": "2021-10-28 16:32:33",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)披露定增结果：实控人获配4000万元 华夏基金、UBS等在列",
    "href": "http://stock.jrj.com.cn/2021/09/27162033524110.shtml",
    "datetime": "2021-09-27 16:20:33",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)上半年实现净利721.72万元 同比扭亏",
    "href": "http://stock.jrj.com.cn/2021/08/25184133317912.shtml",
    "datetime": "2021-08-25 18:41:54",
    "code": "300683"
  },
  {
    "title": "海特生物2021年半年度净利721.72万元 同比扭亏为盈",
    "href": "http://stock.jrj.com.cn/2021/08/25183433317888.shtml",
    "datetime": "2021-08-25 18:34:59",
    "code": "300683"
  },
  {
    "title": "海特生物公布2021年半年报 营收同比增长17.26%",
    "href": "http://stock.jrj.com.cn/2021/08/25180433317999.shtml",
    "datetime": "2021-08-25 18:04:10",
    "code": "300683"
  },
  {
    "title": "海特生物拟对西威埃进行增资3000万元 增资完成后持有西威埃13.64%的股权",
    "href": "http://stock.jrj.com.cn/2021/07/21193833131143.shtml",
    "datetime": "2021-07-21 19:38:41",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：以现金3000万元对西威埃进行增资",
    "href": "http://stock.jrj.com.cn/2021/07/21191733131083.shtml",
    "datetime": "2021-07-21 19:17:34",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：向特定对象发行股票决议有效期及授权有效期拟延期",
    "href": "http://stock.jrj.com.cn/2021/07/12202433084242.shtml",
    "datetime": "2021-07-12 20:24:50",
    "code": "300683"
  },
  {
    "title": "海特生物：北京沙东主要从事国家一类新药CPT的研究 暂未开展其他药物研究",
    "href": "http://stock.jrj.com.cn/2021/06/21162432969784.shtml",
    "datetime": "2021-06-21 16:24:25",
    "code": "300683"
  },
  {
    "title": "海特生物：受理号CYHS2101160的产品为注射用帕瑞昔布钠",
    "href": "http://stock.jrj.com.cn/2021/06/21160032969656.shtml",
    "datetime": "2021-06-21 16:00:50",
    "code": "300683"
  },
  {
    "title": "海特生物：CAR-T是目前癌症治疗领域的新产品",
    "href": "http://stock.jrj.com.cn/2021/06/21155032969584.shtml",
    "datetime": "2021-06-21 15:50:49",
    "code": "300683"
  },
  {
    "title": "海特生物：荆门汉瑞项目进展顺利 未来主要从事高端原料药和CDMO业务 公司目前正在与意向客户洽谈中",
    "href": "http://stock.jrj.com.cn/2021/06/17213832949990.shtml",
    "datetime": "2021-06-17 21:38:43",
    "code": "300683"
  },
  {
    "title": "海特生物：检测微小残留病是北京沙东未来研发方向不会影响CPT注册申请工作",
    "href": "http://stock.jrj.com.cn/2021/06/08065932890579.shtml",
    "datetime": "2021-06-08 06:59:50",
    "code": "300683"
  },
  {
    "title": "海特生物：公司荆门原料药生产基地项目建设进展顺利",
    "href": "http://stock.jrj.com.cn/2021/06/07214132889059.shtml",
    "datetime": "2021-06-07 21:41:03",
    "code": "300683"
  },
  {
    "title": "海特生物：CPT为目前正处于Pre-NDA阶段",
    "href": "http://stock.jrj.com.cn/2021/05/31153332849471.shtml",
    "datetime": "2021-05-31 15:33:18",
    "code": "300683"
  },
  {
    "title": "海特生物：公司对ADC药物暂无实质性的研究和开发计划",
    "href": "http://stock.jrj.com.cn/2021/05/31153132849467.shtml",
    "datetime": "2021-05-31 15:31:16",
    "code": "300683"
  },
  {
    "title": "海特生物：公司在研产品中有注射用帕瑞昔布钠",
    "href": "http://stock.jrj.com.cn/2021/05/31153132849464.shtml",
    "datetime": "2021-05-31 15:31:06",
    "code": "300683"
  },
  {
    "title": "海特生物：荆门汉瑞目前准备申请药品生产许可证",
    "href": "http://stock.jrj.com.cn/2021/05/31153032849466.shtml",
    "datetime": "2021-05-31 15:30:51",
    "code": "300683"
  },
  {
    "title": "海特生物：公司暂无鼠神经生长因子海外拓展计划",
    "href": "http://stock.jrj.com.cn/2021/05/12113332741065.shtml",
    "datetime": "2021-05-12 11:33:30",
    "code": "300683"
  },
  {
    "title": "海特生物：公司未研究开发NKG2A的抗体药物",
    "href": "http://stock.jrj.com.cn/2021/05/12113132741050.shtml",
    "datetime": "2021-05-12 11:31:48",
    "code": "300683"
  },
  {
    "title": "海特生物：沙东没有进行与TNFR2的相关研发和专利",
    "href": "http://stock.jrj.com.cn/2021/05/12112232740991.shtml",
    "datetime": "2021-05-12 11:22:34",
    "code": "300683"
  },
  {
    "title": "【龙虎榜】海特生物4月30日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/04/30180232488216.shtml",
    "datetime": "2021-04-30 18:02:33",
    "code": "300683"
  },
  {
    "title": "仿制药、新冠检测概念再度走强 东方生物海特生物等大涨",
    "href": "http://stock.jrj.com.cn/2021/04/30101832485243.shtml",
    "datetime": "2021-04-30 10:18:00",
    "code": "300683"
  },
  {
    "title": "海特生物2021年第一季度净利1452.91万增长241.82% 本期业务增长",
    "href": "http://stock.jrj.com.cn/2021/04/24202532435802.shtml",
    "datetime": "2021-04-24 20:25:07",
    "code": "300683"
  },
  {
    "title": "海特生物2020年亏损2502.57万 董事长陈亚薪酬63.43万",
    "href": "http://stock.jrj.com.cn/2021/04/24092532434661.shtml",
    "datetime": "2021-04-24 09:25:36",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)拟向子公司蔚嘉制药提供1000万元借款",
    "href": "http://stock.jrj.com.cn/2021/03/26164332223033.shtml",
    "datetime": "2021-03-26 16:43:13",
    "code": "300683"
  },
  {
    "title": "海特生物：产品销量及利润下降，2020年业绩预亏超2000万",
    "href": "http://stock.jrj.com.cn/2021/01/21083131734212.shtml",
    "datetime": "2021-01-21 08:31:46",
    "code": "300683"
  },
  {
    "title": "海特生物2020年预计亏损2300万-3000万 受医药行业政策调整产品销售收入及利润下降",
    "href": "http://stock.jrj.com.cn/2021/01/20195931731112.shtml",
    "datetime": "2021-01-20 19:59:56",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)2020年业绩转亏 预亏2300万元-3000万元",
    "href": "http://stock.jrj.com.cn/2021/01/20160531729010.shtml",
    "datetime": "2021-01-20 16:05:58",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)拟将对沙东生物提供借款额度新增5000万元",
    "href": "http://stock.jrj.com.cn/2021/01/06193731643212.shtml",
    "datetime": "2021-01-06 19:37:44",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：定增申请获证监会注册批复",
    "href": "http://stock.jrj.com.cn/2020/12/29174131596152.shtml",
    "datetime": "2020-12-29 17:41:20",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：药品生产许可证变更 新增生产范围“注射用重组变构人肿瘤坏死因子相关凋亡诱导配体”",
    "href": "http://stock.jrj.com.cn/2020/12/28182831587433.shtml",
    "datetime": "2020-12-28 18:28:51",
    "code": "300683"
  },
  {
    "title": "海特生物(300683.SZ)：就收购蔚嘉制药67%股权 已完成工商变更登记手续",
    "href": "http://stock.jrj.com.cn/2020/12/10160431456372.shtml",
    "datetime": "2020-12-10 16:04:09",
    "code": "300683"
  },
  {
    "title": "海特生物：为推动公司API事业发展 拟7035万元购买蔚嘉制药67%股权",
    "href": "http://stock.jrj.com.cn/2020/11/13183931276817.shtml",
    "datetime": "2020-11-13 18:39:29",
    "code": "300683"
  },
  {
    "title": "海特生物2020年前三季度亏损1052.64万 投资收益同比下滑",
    "href": "http://stock.jrj.com.cn/2020/10/26211531136277.shtml",
    "datetime": "2020-10-26 21:15:23",
    "code": "300683"
  },
  {
    "title": "海特生物2020年上半年亏损377.96万由盈转亏 主要产品金路捷销售下降",
    "href": "http://stock.jrj.com.cn/2020/09/01213330655607.shtml",
    "datetime": "2020-09-01 21:33:51",
    "code": "300683"
  },
  {
    "title": "海特生物：拟定增募资不超过9.75亿元 用于高端原料药生产基地I期项目等",
    "href": "http://stock.jrj.com.cn/2020/07/14184530240464.shtml",
    "datetime": "2020-07-14 18:45:18",
    "code": "300683"
  },
  {
    "title": "海特生物拟筹划非公开发行股票事项",
    "href": "http://stock.jrj.com.cn/2020/06/22181329989996.shtml",
    "datetime": "2020-06-22 18:13:37",
    "code": "300683"
  },
  {
    "title": "海特生物：拟定增募资用于重组变构人肿瘤坏死因子相关项目",
    "href": "http://stock.jrj.com.cn/2020/06/22163129989322.shtml",
    "datetime": "2020-06-22 16:31:41",
    "code": "300683"
  },
  {
    "title": "[互动]海特生物：CPT的生产基地会设在武汉 将在获得批件后投产",
    "href": "http://stock.jrj.com.cn/2020/05/12142829650045.shtml",
    "datetime": "2020-05-12 14:28:14",
    "code": "300683"
  },
  {
    "title": "海特生物2019年净利6303.51万 同比下滑33.04%",
    "href": "http://stock.jrj.com.cn/2020/04/27235029398908.shtml",
    "datetime": "2020-04-27 23:50:02",
    "code": "300683"
  },
  {
    "title": "海特生物第一季度盈利425.06万同比下滑85.76% 研发费用增加",
    "href": "http://stock.jrj.com.cn/2020/04/27221129398404.shtml",
    "datetime": "2020-04-27 22:11:26",
    "code": "300683"
  },
  {
    "title": "海特生物：子公司新冠病毒检测试剂盒通过欧盟CE符合性声明",
    "href": "http://stock.jrj.com.cn/2020/04/17183729314985.shtml",
    "datetime": "2020-04-17 18:37:00",
    "code": "300683"
  },
  {
    "title": "离汉通道开启第一天施工队进场 海特生物高端原料药基地奠基",
    "href": "http://stock.jrj.com.cn/2020/04/16170529305511.shtml",
    "datetime": "2020-04-16 17:05:11",
    "code": "300683"
  },
  {
    "title": "海特生物2020年一季度预计净利298.55万元–895.64万元 同比下降70%-90%",
    "href": "http://stock.jrj.com.cn/2020/04/09191429248517.shtml",
    "datetime": "2020-04-09 19:14:29",
    "code": "300683"
  },
  {
    "title": "海特生物：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/04/09172029246676.shtml",
    "datetime": "2020-04-09 17:20:01",
    "code": "300683"
  },
  {
    "title": "海特生物最新筹码趋于集中",
    "href": "http://stock.jrj.com.cn/hotstock/2020/04/02112229176174.shtml",
    "datetime": "2020-04-02 11:22:00",
    "code": "300683"
  },
  {
    "title": "海特生物翻倍行情引关注 董事长陈亚：股价表现是信任和重托",
    "href": "http://stock.jrj.com.cn/2020/03/22142429075572.shtml",
    "datetime": "2020-03-22 14:24:32",
    "code": "300683"
  },
  {
    "title": "13日公司新闻聚焦：一汽轿车270亿重组案获批 海特生物再提示风险",
    "href": "http://stock.jrj.com.cn/2020/03/13091929017405.shtml",
    "datetime": "2020-03-13 09:19:00",
    "code": "300683"
  },
  {
    "title": "海特生物：新药研发受多方面影响",
    "href": "http://stock.jrj.com.cn/2020/03/12172929010683.shtml",
    "datetime": "2020-03-12 17:29:35",
    "code": "300683"
  },
  {
    "title": "海特生物十连板提示风险：新药研发受多方面影响",
    "href": "http://stock.jrj.com.cn/2020/03/12163429010415.shtml",
    "datetime": "2020-03-12 16:34:00",
    "code": "300683"
  },
  {
    "title": "涨停复盘：口罩概念延续分化 新基建仍是资金主攻方向",
    "href": "http://stock.jrj.com.cn/2020/03/12161829010241.shtml",
    "datetime": "2020-03-12 16:18:39",
    "code": "300683"
  },
  {
    "title": "10连板海特生物：新药研发受到技术、审批、政策等多方面的影响",
    "href": "http://stock.jrj.com.cn/2020/03/12161529010208.shtml",
    "datetime": "2020-03-12 16:15:18",
    "code": "300683"
  },
  {
    "title": "海特生物：新药研发受到技术、审批、政策等多方面的影响",
    "href": "http://stock.jrj.com.cn/2020/03/12161529010209.shtml",
    "datetime": "2020-03-12 16:15:18",
    "code": "300683"
  },
  {
    "title": "参股子公司北京沙东CPTⅢ期完成揭盲 海特生物连续10日涨停",
    "href": "http://stock.jrj.com.cn/2020/03/12102629007870.shtml",
    "datetime": "2020-03-12 10:26:27",
    "code": "300683"
  },
  {
    "title": "海特生物最新筹码趋于集中",
    "href": "http://stock.jrj.com.cn/hotstock/2020/03/11160729001628.shtml",
    "datetime": "2020-03-11 16:07:00",
    "code": "300683"
  },
  {
    "title": "参股子公司北京沙东CPTⅢ期完成揭盲 海特生物连续8日涨停",
    "href": "http://stock.jrj.com.cn/2020/03/10103828989569.shtml",
    "datetime": "2020-03-10 10:38:11",
    "code": "300683"
  },
  {
    "title": "海特生物：新药揭盲结果不会对公司近期业绩产生重大影响",
    "href": "http://stock.jrj.com.cn/2020/03/05183728960319.shtml",
    "datetime": "2020-03-05 18:37:36",
    "code": "300683"
  },
  {
    "title": "海特生物：新药不会对公司近期业绩产生重大影响",
    "href": "http://stock.jrj.com.cn/2020/03/05163128959626.shtml",
    "datetime": "2020-03-05 16:31:25",
    "code": "300683"
  },
  {
    "title": "参股子公司北京沙东CPTⅢ期完成揭盲 海特生物连续4日涨停",
    "href": "http://stock.jrj.com.cn/2020/03/04095128949958.shtml",
    "datetime": "2020-03-04 09:51:15",
    "code": "300683"
  },
  {
    "title": "参股子公司北京沙东CPTⅢ期完成揭盲 海特生物涨停",
    "href": "http://stock.jrj.com.cn/2020/03/03141728944212.shtml",
    "datetime": "2020-03-03 14:17:44",
    "code": "300683"
  },
  {
    "title": "海特生物2019年净利润6948.87万元下滑26.18% 受医药行业政策调整下滑",
    "href": "http://stock.jrj.com.cn/2020/02/28105928912384.shtml",
    "datetime": "2020-02-28 10:59:44",
    "code": "300683"
  },
  {
    "title": "海特生物董秘陈煌：疫情下在线办公 协调沟通能力成考验",
    "href": "http://stock.jrj.com.cn/2020/02/26152028897465.shtml",
    "datetime": "2020-02-26 15:20:58",
    "code": "300683"
  },
  {
    "title": "子公司多年前就能生产新冠检测试剂？ 海特生物：非检测2019新冠病毒的产品",
    "href": "http://stock.jrj.com.cn/2020/02/11193528811048.shtml",
    "datetime": "2020-02-11 19:35:45",
    "code": "300683"
  },
  {
    "title": "海特生物：目前无法开展正常生产经营活动 但无重大影响",
    "href": "http://stock.jrj.com.cn/2020/02/03112528752993.shtml",
    "datetime": "2020-02-03 11:25:00",
    "code": "300683"
  },
  {
    "title": "武汉本地企业海特生物：子公司珠海海泰无本次肺炎检测产品",
    "href": "http://stock.jrj.com.cn/2020/01/22104028719216.shtml",
    "datetime": "2020-01-22 10:40:23",
    "code": "300683"
  },
  {
    "title": "海特生物2019年预计净利6119万元–7531万元",
    "href": "http://stock.jrj.com.cn/2020/01/20192428707669.shtml",
    "datetime": "2020-01-20 19:24:05",
    "code": "300683"
  },
  {
    "title": "海特生物：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/20173028706727.shtml",
    "datetime": "2020-01-20 17:30:00",
    "code": "300683"
  },
  {
    "title": "海特生物第三季度盈利1232万 同比下滑58.26%",
    "href": "http://stock.jrj.com.cn/2019/10/25222428302682.shtml",
    "datetime": "2019-10-25 22:24:32",
    "code": "300683"
  },
  {
    "title": "海特生物2019年前三季度净利约6459万元–7219万元 研发费用增长",
    "href": "http://stock.jrj.com.cn/2019/10/12074828236098.shtml",
    "datetime": "2019-10-12 07:48:10",
    "code": "300683"
  },
  {
    "title": "海特生物：2019年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/10/11180028234085.shtml",
    "datetime": "2019-10-11 18:00:02",
    "code": "300683"
  },
  {
    "title": "海特生物为全资子公司提供银行授信担保",
    "href": "http://stock.jrj.com.cn/2019/09/25210328180331.shtml",
    "datetime": "2019-09-25 21:03:52",
    "code": "300683"
  },
  {
    "title": "海特生物2019年上半年净利5581万 加大产品覆盖面提高产品市场占有率",
    "href": "http://stock.jrj.com.cn/2019/08/26173228034275.shtml",
    "datetime": "2019-08-26 17:32:52",
    "code": "300683"
  },
  {
    "title": "海特生物董事严洁增持承诺\"撞上\"半年报窗口期 15.9万股买入违规",
    "href": "http://stock.jrj.com.cn/2019/08/16112227986564.shtml",
    "datetime": "2019-08-16 11:22:37",
    "code": "300683"
  },
  {
    "title": "半年报披露敏感期 海特生物董事违规买入15.9万股",
    "href": "http://stock.jrj.com.cn/2019/08/15201727983154.shtml",
    "datetime": "2019-08-15 20:17:32",
    "code": "300683"
  },
  {
    "title": "海特生物：2019年半年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/07/10182027822950.shtml",
    "datetime": "2019-07-10 18:20:00",
    "code": "300683"
  },
  {
    "title": "海特生物上半年预盈5111万至6041万 一子公司并表导致利润增长",
    "href": "http://stock.jrj.com.cn/2019/07/10175127822855.shtml",
    "datetime": "2019-07-10 17:51:20",
    "code": "300683"
  },
  {
    "title": "海特生物去年净利9414万同比下滑34% 董事长陈亚年薪58万",
    "href": "http://stock.jrj.com.cn/2019/04/20171127434375.shtml",
    "datetime": "2019-04-20 17:11:31",
    "code": "300683"
  },
  {
    "title": "海特生物副总经理李汝霖辞职 公司去年净利同比下滑34%",
    "href": "http://stock.jrj.com.cn/2019/04/20171027434370.shtml",
    "datetime": "2019-04-20 17:10:32",
    "code": "300683"
  },
  {
    "title": "不按约定时间披露年报 海特生物制药收监管函",
    "href": "http://stock.jrj.com.cn/2019/04/19193827430119.shtml",
    "datetime": "2019-04-19 19:38:54",
    "code": "300683"
  },
  {
    "title": "海特生物发布年报 营收利润双降",
    "href": "http://stock.jrj.com.cn/2019/04/19183127429729.shtml",
    "datetime": "2019-04-19 18:31:29",
    "code": "300683"
  },
  {
    "title": "海特生物：2018年净利同比下跌33.89% 拟10派2.00元",
    "href": "http://stock.jrj.com.cn/2019/04/19165127429227.shtml",
    "datetime": "2019-04-19 16:51:32",
    "code": "300683"
  },
  {
    "title": "海特生物：2018年净利同比降34% 拟10派2元",
    "href": "http://stock.jrj.com.cn/2019/04/19161227428961.shtml",
    "datetime": "2019-04-19 16:12:00",
    "code": "300683"
  },
  {
    "title": "海特生物临时停牌原因：年报上传超时",
    "href": "http://stock.jrj.com.cn/2019/04/19104527427637.shtml",
    "datetime": "2019-04-19 10:45:00",
    "code": "300683"
  },
  {
    "title": "因年报上传超时海特生物临时停牌",
    "href": "http://stock.jrj.com.cn/2019/04/19101127427419.shtml",
    "datetime": "2019-04-19 10:11:32",
    "code": "300683"
  },
  {
    "title": "海特生物：一季度净利同比增长20%—45%",
    "href": "http://stock.jrj.com.cn/2019/04/10014127357232.shtml",
    "datetime": "2019-04-10 01:41:01",
    "code": "300683"
  },
  {
    "title": "海特生物：2019年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/04/04180027322074.shtml",
    "datetime": "2019-04-04 18:00:00",
    "code": "300683"
  },
  {
    "title": "海特生物：一季度净利预增20%-45%",
    "href": "http://stock.jrj.com.cn/2019/04/04162727321317.shtml",
    "datetime": "2019-04-04 16:27:13",
    "code": "300683"
  },
  {
    "title": "海特生物拟10亿建高端医药原料药生产基地及制剂项目",
    "href": "http://stock.jrj.com.cn/2018/12/06202425464342.shtml",
    "datetime": "2018-12-06 20:24:25",
    "code": "300683"
  },
  {
    "title": "海特生物：拟10亿元投建高端医药原料药生产基地及制剂项目",
    "href": "http://stock.jrj.com.cn/2018/12/06202325464365.shtml",
    "datetime": "2018-12-06 20:23:00",
    "code": "300683"
  },
  {
    "title": "海特生物拟10亿元投建高端医药原料药生产基地及制剂项目",
    "href": "http://stock.jrj.com.cn/2018/12/06184125463876.shtml",
    "datetime": "2018-12-06 18:41:13",
    "code": "300683"
  },
  {
    "title": "海特生物收购议案通过 将切入小分子化药领域",
    "href": "http://stock.jrj.com.cn/2018/10/10002125178872.shtml",
    "datetime": "2018-10-10 00:21:30",
    "code": "300683"
  },
  {
    "title": "海特生物：拟4.5亿元收购天津汉康100%股权",
    "href": "http://stock.jrj.com.cn/hotstock/2018/09/14075925090461.shtml",
    "datetime": "2018-09-14 07:59:56",
    "code": "300683"
  },
  {
    "title": "海特生物：拟4.5亿元收购天津汉康",
    "href": "http://stock.jrj.com.cn/2018/09/13183525088450.shtml",
    "datetime": "2018-09-13 18:35:00",
    "code": "300683"
  },
  {
    "title": "[加急]破发股海特生物迎解禁 销售费高企居行业之首",
    "href": "http://stock.jrj.com.cn/2018/08/08072324922192.shtml",
    "datetime": "2018-08-08 07:23:31",
    "code": "300683"
  },
  {
    "title": "海特生物：北京沙东三期临床试验目前仍在顺利推进",
    "href": "http://stock.jrj.com.cn/2018/08/02154024896084.shtml",
    "datetime": "2018-08-02 15:40:00",
    "code": "300683"
  },
  {
    "title": "海特生物：拟以现金支付方式收购天津汉康",
    "href": "http://stock.jrj.com.cn/hotstock/2018/08/01080024887706.shtml",
    "datetime": "2018-08-01 08:00:07",
    "code": "300683"
  },
  {
    "title": "海特生物：关于变更购买资产交易方式及公司股票复牌的公告",
    "href": "http://stock.jrj.com.cn/2018/07/31205024886412.shtml",
    "datetime": "2018-07-31 20:50:00",
    "code": "300683"
  },
  {
    "title": "海特生物：拟以现金支付方式收购天津汉康 明日复牌",
    "href": "http://stock.jrj.com.cn/2018/07/31192024886148.shtml",
    "datetime": "2018-07-31 19:20:00",
    "code": "300683"
  },
  {
    "title": "海特生物：变更购买资产交易方式 8月1日起复牌",
    "href": "http://stock.jrj.com.cn/2018/07/31191024886105.shtml",
    "datetime": "2018-07-31 19:10:14",
    "code": "300683"
  },
  {
    "title": "海特生物变更购买资产交易方式 8月1日起复牌",
    "href": "http://stock.jrj.com.cn/2018/07/31190924886111.shtml",
    "datetime": "2018-07-31 19:09:58",
    "code": "300683"
  },
  {
    "title": "海特生物拟收购汉康医药 明日起转入重大资产重组程序继续停牌",
    "href": "http://stock.jrj.com.cn/2018/05/23201024581109.shtml",
    "datetime": "2018-05-23 20:10:00",
    "code": "300683"
  },
  {
    "title": "海特生物：筹划购买资产事项",
    "href": "http://stock.jrj.com.cn/hotstock/2018/05/10075924519271.shtml",
    "datetime": "2018-05-10 07:59:49",
    "code": "300683"
  },
  {
    "title": "海特生物：筹划重大事项 股票5月10日起停牌",
    "href": "http://stock.jrj.com.cn/2018/05/10070124518805.shtml",
    "datetime": "2018-05-10 07:01:00",
    "code": "300683"
  },
  {
    "title": "海特生物：关于重大事项停牌的公告",
    "href": "http://stock.jrj.com.cn/2018/05/09202024517748.shtml",
    "datetime": "2018-05-09 20:20:00",
    "code": "300683"
  },
  {
    "title": "海特生物：筹划重大事项 明起停牌",
    "href": "http://stock.jrj.com.cn/2018/05/09195524517645.shtml",
    "datetime": "2018-05-09 19:55:00",
    "code": "300683"
  },
  {
    "title": "海特生物停牌筹划涉及购买资产重大事项",
    "href": "http://stock.jrj.com.cn/2018/05/09194924517639.shtml",
    "datetime": "2018-05-09 19:49:53",
    "code": "300683"
  },
  {
    "title": "海特生物一季度利润下滑23.13% 主营产品受限正尝试拓展",
    "href": "http://stock.jrj.com.cn/2018/04/26200024458583.shtml",
    "datetime": "2018-04-26 20:00:04",
    "code": "300683"
  },
  {
    "title": "海特生物：未来将加大诊断试剂产品的研发",
    "href": "http://stock.jrj.com.cn/2018/04/24151524441010.shtml",
    "datetime": "2018-04-24 15:15:00",
    "code": "300683"
  },
  {
    "title": "海特生物依赖单一产品风险暴露业绩变脸",
    "href": "http://stock.jrj.com.cn/2018/04/09103724393796.shtml",
    "datetime": "2018-04-09 10:37:22",
    "code": "300683"
  },
  {
    "title": "海特生物2017年度净利1.42亿元 拟10股派3元",
    "href": "http://stock.jrj.com.cn/2018/04/08184624358639.shtml",
    "datetime": "2018-04-08 18:46:00",
    "code": "300683"
  },
  {
    "title": "海特生物：2017年年度报告主要财务指标及分配预案",
    "href": "http://stock.jrj.com.cn/2018/04/08164024358315.shtml",
    "datetime": "2018-04-08 16:40:00",
    "code": "300683"
  },
  {
    "title": "海特生物：2018年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/04/08162024358249.shtml",
    "datetime": "2018-04-08 16:20:00",
    "code": "300683"
  },
  {
    "title": "海特生物获得政府奖励700万元",
    "href": "http://stock.jrj.com.cn/2017/12/04172923738149.shtml",
    "datetime": "2017-12-04 17:29:00",
    "code": "300683"
  },
  {
    "title": "海特生物8月8日创业板上市 定位分析",
    "href": "http://stock.jrj.com.cn/ipo/2017/08/07085922851909.shtml",
    "datetime": "2017-08-07 08:59:32",
    "code": "300683"
  },
  {
    "title": "海特生物网上定价发行中签率0.0258%",
    "href": "http://stock.jrj.com.cn/ipo/2017/07/27204022808378.shtml",
    "datetime": "2017-07-27 20:40:25",
    "code": "300683"
  },
  {
    "title": "海特生物实控人兄长曾因四环药业虚假陈述被处罚",
    "href": "http://stock.jrj.com.cn/2017/06/02092222564478.shtml",
    "datetime": "2017-06-02 09:22:54",
    "code": "300683"
  },
  {
    "title": "海特生物IPO:收入依赖单一产品 2016学术推广费为净利逾3倍",
    "href": "http://stock.jrj.com.cn/2017/05/04085922424625.shtml",
    "datetime": "2017-05-04 08:59:00",
    "code": "300683"
  },
  {
    "title": "扬子新材拟收购武汉海特生物100%股权 26日起停牌",
    "href": "http://stock.jrj.com.cn/2015/10/26105919980740.shtml",
    "datetime": "2015-10-26 10:59:33",
    "code": "300683"
  }
]